CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it ...

CARGO Therapeutic announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 ...

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...

Investing.com -- Shares of CARGO Therapeutics , Inc. (NASDAQ: CRGX) plummeted 75% following the company's decision to discontinue its Phase 2 clinical trial for firicabtagene autoleucel, citing ...

Truist Securities revised its position on Cargo Therapeutics (NASDAQ:CRGX), currently trading at $13.19 with a market ...

CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm ...

CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX ...

Piper Sandler adjusted its stance on Cargo Therapeutics (NASDAQ:CRGX), downgrading the stock from Overweight to Neutral and ...

Benchmark upgraded Meta Platforms (META) to Buy from Hold with a $820 price target, citing a "strong" 2025 core business ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45.

The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.